Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation (rTMS) with Precise Localization for Motor Symptoms in Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study

What this Trial Is About

Tardive Dyskinesia (TD) is a movement disorder caused by long-term use of dopamine receptor blockers and related drugs. It results in involuntary movements that persist and cause lasting neurological damage, significantly impacting patients' daily functioning. Researchers are evaluating whether repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, can improve motor symptoms in people with TD. This study focuses on a specific rTMS mode called continuous theta-Burst Stimulation (cTBS), which may offer more lasting benefits through precise brain targeting. Participants will receive rTMS treatment for 14 days using cTBS. Before treatment, they will undergo an MRI scan to create a personalized brain map, allowing precise localization of the stimulation areas in the motor and sensory networks. The study includes two groups: one receiving active rTMS and the other receiving sham (placebo) rTMS. This design allows comparison to assess the treatment's effect on TD motor symptoms under double-blind conditions. During the study, participants will be regularly assessed using the Abnormal Involuntary Movement Scale (AIMS) over two years to measure changes in abnormal movements. Researchers will monitor safety and treatment effects throughout this period. Participation involves MRI scans, rTMS sessions, and follow-up visits to evaluate motor symptoms and overall response to the intervention.

Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD